Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Weak Cash Flow ⢠Earnings Quality HCM has strong reported profitability and liquidity with modest leverage, but negative operating/free cash flow, investment-driven earnings, and limited current-period profit data warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong uptrend ⢠Resistance tested ⢠Support holding Support Level: $12.18â$12.26 Resistance Level: $12.60â$12.65 HCM's strong last-month uptrend remains constructive above $12.18â$12.26 support, but resistance near $12.60â$12.65 and near-overbought momentum suggest caution.
Sentiment & News
Key News Insights: ⢠Revenue Growth ⢠Phase III Success ⢠China Approval HUTCHMED's strong oncology revenue, positive Phase III data, and new China approval reinforce its growth outlook despite mixed broader lung-cancer news.
AI Summary
HUTCHMED's global oncology momentumâespecially FRUZAQLA expansion and SAFFRON's Phase III successâstrengthens its commercialization upside, but investors should not treat FY2025's investment-driven profit as evidence of a self-sustaining business until product growth produces positive operating cash flow.
Description
HUTCHMED (China) Limited is a Hong Kongâbased biopharmaceutical company that discovers, develops and commercializes targeted small molecules and immunotherapies primarily for oncology and selected immunological conditions. Its pipeline comprises multiple classes of targeted agents and epigenetic therapies addressing a range of solid tumors and hematologic malignancies, and the company operates through Oncology/Immunology and Other Ventures segments. HUTCHMED maintains collaboration agreements with several global and Chinese biopharma firms and was incorporated in 2000 (name changed from Hutchison China MediTech Limited in 2021).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | HCM | HUTCHMED (China) Limited | Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support. | Active | +0.0% |